Chembio Diagnostics Inc. [CEMI] has traded in a range of $2.25 to $15.89 in the last 1 year. As of this writing, the stock is at $5.90, up 0.51%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, CEMI shares are 16.37% up with the monthly amount drift of 46.40% and seems well in a long time frame.

On 4, August 2020, CEMI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2020 in the Class Action Filed on Behalf of Chembio Diagnostics, Inc. Limited Shareholders. According to news published on Yahoo Finance, New York, New York–(Newsfile Corp. – August 4, 2020) – The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Chembio Diagnostics, Inc. (NASDAQ: CEMI) alleging that the Company violated federal securities laws.

Analyst Birdseye View:

The most recent analyst activity for Chembio Diagnostics Inc. [NASDAQ:CEMI] stock was on June 17, 2020, when it was Downgrade with a Hold rating from Craig Hallum. On June 17, 2020, Canaccord Genuity Downgrade a Hold rating and boosted its price target on this stock to $7. On May 26, 2020, Robert W. Baird Initiated an Outperform rating and increased its price target to $21. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and decreased its price target to $6. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and boosted its amount target on this stock to $5. On December 19, 2018, Dougherty & Company Initiated a Buy rating. On August 11, 2016 The Benchmark Company Reiterated a Speculative buy rating and elevated its amount target to $9.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.25 and a peak of $15.89. Right now, the middling Wall Street analyst 12-month amount mark is $5.00. At the most recent market close, shares of Chembio Diagnostics Inc. [NASDAQ:CEMI] were valued at $5.90. According to the average price forecast, investors can expect a potential return of 10.0%.


Chembio Diagnostics Inc. [NASDAQ:CEMI] most recently reported quarterly sales of 6.86 billion, which represented growth of -18.80%. This publicly-traded organization’s revenue is $106,370 per employee, while its income is -$42,207 per employee. This company’s Gross Margin is currently 33.40%, its Operating Margin is -44.10%, its Pretax Margin is -41.13, and its Net Margin is -39.68. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -24.65, -47.68, -30.26 and -33.22 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 51.55 and the whole liability to whole assets at 36.51. It shows enduring liability to the whole principal at 49.96 and enduring liability to assets at 0.35 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 5.67 points at 1st support level, the second support level is making up to 5.44. But as of 1st resistance point, this stock is sitting at 6.16 and at 6.42 for 2nd resistance point.

Chembio Diagnostics Inc. [CEMI] reported its earnings at -$0.29 per share in the fiscal quarter closing of 3/30/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.23/share signifying the difference of -0.06 and -26.10% surprise value. Comparing the previous quarter ending of 12/30/2019, the stated earnings were -$0.24 calling estimates for -$0.24/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Chembio Diagnostics Inc. [NASDAQ:CEMI] is 3.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.24 and it’s amount to book ratio is 3.36.

Insider Stories

The most recent insider trade was by Potthoff John Gary, Director, and it was the purchase of 10000.0 shares on Nov 11.